Aimmune Therapeutics Inc. (NASDAQ:AIMT) traded down 2.5% during trading on Thursday . The stock traded as low as $14.06 and last traded at $14.44, with a volume of 123,276 shares. The stock had previously closed at $14.81.

Several equities research analysts have commented on the company. Wedbush reissued an “outperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a report on Monday, June 13th. Bank of America Corp. reissued a “buy” rating on shares of Aimmune Therapeutics in a report on Monday, May 16th. Zacks Investment Research raised Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Friday, May 20th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $38.00 target price on shares of Aimmune Therapeutics in a report on Tuesday, May 17th. Finally, Credit Suisse Group AG reissued a “buy” rating and issued a $35.00 target price on shares of Aimmune Therapeutics in a report on Friday, August 19th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $33.40.

The firm’s market cap is $614.37 million. The stock’s 50-day moving average price is $12.33 and its 200 day moving average price is $13.78.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.01. On average, analysts predict that Aimmune Therapeutics Inc. will post ($1.71) EPS for the current year.

In other Aimmune Therapeutics news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of Aimmune Therapeutics stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $15.23, for a total transaction of $3,655,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

A hedge fund recently raised its stake in Aimmune Therapeutics stock. RS Investment Management Co. LLC boosted its position in Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 12.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 804,143 shares of the company’s stock after buying an additional 88,180 shares during the period. RS Investment Management Co. LLC owned about 1.90% of Aimmune Therapeutics worth $14,836,000 at the end of the most recent quarter.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.